We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+4.61%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$870M
AUM Growth
-$103M
Cap. Flow
-$99.3M
Cap. Flow %
-11.41%
Top 10 Hldgs %
34.33%
Holding
104
New
12
Increased
20
Reduced
55
Closed
10

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$31.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$18.9M
3
DXCM icon
DexCom
DXCM
+$12.6M
4
COO icon
Cooper Companies
COO
+$10.8M
5
ELV icon
Elevance Health
ELV
+$10.4M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$24.2M
2
MRK icon
Merck
MRK
+$22.8M
3
CI icon
Cigna
CI
+$15.1M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$14.7M
5
BSX icon
Boston Scientific
BSX
+$14.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TECH icon
101
Bio-Techne
TECH
$11.2B
– –
-3,000
Closed -$216K
TMDX icon
102
Transmedics
TMDX
$2.99B
– –
-38,000
Closed -$2.37M
UHS icon
103
Universal Health Services
UHS
$9.96B
– –
-30,900
Closed -$5.54M
ITCI
104
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-176,000
Closed -$14.7M
1 2 3 4
5

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q1 2025 Portfolio in Review

As of Q1 2025, Rhenman & Partners Asset Management held 104 positions worth $870M, down 11% from $973M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $99.3M in Q1 2025, closing 10 positions and reducing 55 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $14.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Rhenman & Partners Asset Management opened a new position in Bristol-Myers Squibb worth $19.8M.

  • Rhenman & Partners Asset Management's largest Q1 2025 buy was Bristol-Myers Squibb: 325,000 shares worth $19.8M.
  • Rhenman & Partners Asset Management added most to Glaukos in Q1 2025, an estimated $31.1M increase.
  • Rhenman & Partners Asset Management's biggest Q1 2025 reduction was Inspire Medical Systems, cutting an estimated $24.2M.
  • Rhenman & Partners Asset Management fully exited Intra-Cellular Therapies Inc. in Q1 2025, selling an estimated $14.7M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 34% of its $870M portfolio in Q1 2025.
  • Rhenman & Partners Asset Management opened 12 new positions and closed 10 in Q1 2025.
  • Rhenman & Partners Asset Management's portfolio value fell 11% quarter-over-quarter to $870M.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2025, filed 14 May 2025.